Table of Contents
Scholarly Research Exchange
Volume 2008 (2008), Article ID 467264, 5 pages
http://dx.doi.org/10.3814/2008/467264
Clinical Study

Upregulation of Monocyte Chemoattractant Protein-1 (MCP-1) in Early Diabetic Nephropathy in Patients with Type-1 Diabetes Mellitus

1Department of Nephrology, Faculty of Medicine, Tanta University, Gharbia, Egypt
2Department of Internal Medicine, Faculty of Medicine, Tanta University, Gharbia, Egypt
3Urology and Nephrology Center, Mansoura University, Mansoura, Egypt
4Department of Clinical Pathology, Faculty of Medicine, Alazhar University, Cairo, Egypt

Received 25 June 2008; Accepted 10 September 2008

Copyright © 2008 Eid El-Shafey et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Monocyte chemoattractant protein-1 (MCP-1) can directly elicit an inflammatory response by inducing cytokine and adhesion molecule expression in the kidney. We investigated the role of MCP-1 in the development of early nephropathy in patients with type-1 diabetes mellitus, in addition to the effect of high-dose vitamin E treatment (8 weeks) on early stages of diabetic nephropathy. Methods. This study was carried out on 30 type-1 diabetic patients subdivided into two equal groups according to their urinary albumin excretion, in addition to 10 healthy matched volunteers included as controls. MCP-1, glycated hemoglobin (HbA1c), and albuminuria—before and after vitamin E treatment—were measured in all studied groups. Results. Serum MCP-1 and HbA1c were significantly elevated in patients with microalbuminuria and poor glycemic control (941.67±47.03 pg/mL; 16.95±2.74%) compared to normoalbuminuric diabetic patients (622.73±103.23 pg/mL; 7.23±0.86%), and controls (366.60±129.01; 3.35±0.66) (P=.001), respectively. There was positive correlation between MCP-1 and HbA1c. Both MCP-1 and albuminuria decreased significantly after using high-dose vitamin E treatment, though there was no change in HbA1c in type-1 diabetic patients with early nephropathy. Conclusion. These observations suggest that MCP-1 may be involved in the pathogenesis of diabetic nephropathy. High-dose vitamin E may provide a novel form of therapy for the prevention of microvascular complications in type-1 diabetic patients.